Dublin-headquartered Mallinckrodt is taking over smaller rival Endo and planning to list the combined firm on the New York ...

Mallinckrodt and Endo, drugmakers which recently emerged from bankruptcy after a wave of U.S. opioid lawsuits, announced ...

Ireland’s Mallinckrodt will buy U.S. drugmaker Endo in a cash-and-stock deal valued at $6.7 billion. The companies said ...

The two companies are merging after previously filing for bankruptcy due to opioid-related litigation and financial losses.

Mallinckrodt and Endo are merging in a $6.7 billion deal, with a pro forma NYSE listing and $900 million in financing.

The Mallinckrodt-Endo combination will have approximately 5,700 employees at closing, as well as 17 manufacturing facilities, 30 distribution centers, and an operating footprint primarily located in ...

Q4 2024 Earnings Conference Call March 13, 2025 8:00 AM ETCompany ParticipantsLaure Park - Senior Vice President ...

The merger will give the combined entity the financial flexibility to pursue drug licensing deals and broaden its therapeutic ...

Ireland-based Mallinckrodt Pharmaceuticals and Endo Inc (OTCQX: NDOI) have agreed to combine in a stock and cash deal worth ...

Malvern-based Endo has agreed to merge with Mallinckrodt in a cash and stock deal, valuing the combined pharmaceutical ...

Wachtell, Lipton, Rosen & Katz is steering Mallinckrodt Pharmaceuticals and Davis Polk & Wardwell is guiding Endo Inc. in ...

The pairing of Mallinckrodt plc and Endo Inc. is expected to create a pharma heavyweight that will generate $3.6 billion in 2025 revenue after the duo combines their generic pharmaceuticals businesses ...